{"id":296395,"date":"2024-02-28T00:00:00","date_gmt":"2024-02-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0036-2024-biopharma-multiple-sclerosis-unmet-need-unmet-need-multiple-sclerosis-progression\/"},"modified":"2026-04-18T11:22:22","modified_gmt":"2026-04-18T11:22:22","slug":"unnecg0036-2024-biopharma-multiple-sclerosis-unmet-need-unmet-need-multiple-sclerosis-progression-independent-of","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0036-2024-biopharma-multiple-sclerosis-unmet-need-unmet-need-multiple-sclerosis-progression-independent-of\/","title":{"rendered":"Multiple Sclerosis &#8211; Unmet Need &#8211; Unmet Need &#8211; Multiple Sclerosis: Progression Independent of Relapse Activity (US\/EU)"},"content":{"rendered":"<p>Marketed <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>s for multiple sclerosis deliver a high level of efficacy in preventing relapses and relapse-associated worsening of disability (RAW). However, <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> patients still experience disability worsening that is temporally independent of relapses, referred to as progression independent of relapse activity (<abbr data-abbreviation-entity=\"10541\" title=\"progression independent of relapse activity\">PIRA<\/abbr>). <abbr data-abbreviation-entity=\"10541\" title=\"progression independent of relapse activity\">PIRA<\/abbr> may be driven in part by innate immune cells in the central nervous system (<abbr data-abbreviation-entity=\"4768\" title=\"central nervous system\">CNS<\/abbr>). A wave of oral, <abbr data-abbreviation-entity=\"4768\" title=\"central nervous system\">CNS<\/abbr>-penetrant Bruton\u2019s tyrosine kinase inhibitors (<abbr data-abbreviation-entity=\"5619\" title=\"Bruton\u2019s tyrosine kinase\">BTK<\/abbr>i) is in Phase 3, which hold the potential to deliver greater efficacy than current drugs in preventing <abbr data-abbreviation-entity=\"10541\" title=\"progression independent of relapse activity\">PIRA<\/abbr>. This report will examine the influence of <abbr data-abbreviation-entity=\"10541\" title=\"progression independent of relapse activity\">PIRA<\/abbr> and other outcomes on neurologists\u2019 prescribing decisions and their level of satisfaction with current high-efficacy <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>s. It will also gauge the opportunity for emerging therapies to differentiate through an impact on <abbr data-abbreviation-entity=\"10541\" title=\"progression independent of relapse activity\">PIRA<\/abbr> and biomarker endpoints.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How important is a therapy\u2019s impact on <abbr data-abbreviation-entity=\"10541\" title=\"progression independent of relapse activity\">PIRA<\/abbr>, RAW, or biomarker outcomes in neurologists\u2019 selection of an <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>?<\/li>\n<li>How do neurologists rate anti-CD20 <abbr data-abbreviation-entity=\"4880\" title=\"monoclonal antibody\">MAb<\/abbr>s, <abbr data-abbreviation-entity=\"5310\" title=\"sphingosine 1-phosphate\">S1P<\/abbr> modulators, and other <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>s on these attributes?<\/li>\n<li>What is the relative level of need for improved treatment options to preventing <abbr data-abbreviation-entity=\"10541\" title=\"progression independent of relapse activity\">PIRA<\/abbr>?<\/li>\n<li>Based on conjoint analysis and <abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr> simulation, what trade-offs among efficacy, safety, and price are neurologists willing to make for a hypothetical new drug for <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> offering a larger impact on <abbr data-abbreviation-entity=\"10541\" title=\"progression independent of relapse activity\">PIRA<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding <abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 61 U.S. and 34 European neurologists fielded in December 2023<\/p>\n<p><strong>Key companies:<\/strong> TG Therapeutics, Novartis, Merck KGaA \/ EMD Serono, Roche \/ Genentech, Biogen, Sanofi<\/p>\n<p><strong>Key drugs:<\/strong> Briumvi, Fingolimod, Kesimpta, Mavenclad, Mayzent, Ocrevus, Tysabri, tolebrutinib, fenebrutinib, remibrutinib<\/p>\n","protected":false},"template":"","class_list":["post-296395","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-therapy-areas-neurology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296395\/revisions"}],"predecessor-version":[{"id":296626,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296395\/revisions\/296626"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}